OAK-based cochleates as a novel approach to overcome multidrug resistance in bacteria

FASEB Journal

Volumn 24, Issue 12, 2010, Pages 5092-5101

  Livne, L ^a   Epand, R F ^b   Papahadjopoulos Sternberg, B ^c   Epand, R M ^b   Mor, A ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b MCMASTER UNIVERSITY   (Canada)

^c NanoAnalytical Laboratory   (United States)

Author keywords

Host defense peptides; Slow drug release; Systemic therapy

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; GENTAMICIN; LIPOSOME; OLIGOACYLLYSINE; OXACILLIN; PENICILLIN G; PEPTIDE; PIPERACILLIN; RIFAMPICIN; TETRACYCLINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; ASSAY; BACTERIUM; BLOOD; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; EFFUSION; ENCAPSULATION; ESCHERICHIA COLI; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; MUTANT; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; SINGLE DRUG DOSE; SYSTEMIC THERAPY;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS; NEGIBACTERIA;

EID: 78649730782     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.10-167809     Document Type: Article

References (77)

1. Cassell, G. H. (1997) Emergent antibiotic resistance: health risks and economic impact. FEMS Immunol. Med. Microbiol. 18, 271-274
2. Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H. W., Scheld, W. M., Bartlett, J. G., and Edwards, J., Jr. (2008) The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 155-164
3. Cosgrove, S. E., and Carmeli, Y. (2003) The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis. 36, 1433-1437
4. Rice, L. B. (2009) The clinical consequences of antimicrobial resistance. Curr. Opin. Microbiol. 12, 476-481
5. Dzidic, S., Suskovic, J., and Kos, B. (2008) Antibiotic resistance mechanisms in bacteria: biochemical and genetic aspects. Food Technol. Bio/Technol. 46, 11-21
6. Walsh, C. (2000) Molecular mechanisms that confer antibacterial drug resistance. Nature 406, 775-781
7. Hancock, R. E., and Sahl, H. G. (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551-1557
8. Zasloff, M. (2002) Antimicrobial peptides of multicellular organisms. Nature 415, 389-395
9. Brogden, K. A. (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3, 238-250
10. Wu, G. Q., Ding, J. X., Li, L. X., Wang, H. L., Zhao, R., and Shen, Z. L. (2009) Activity of the antimicrobial peptide and thanatin analog S-thanatin on clinical isolates of Klebsiella pneumoniae resistant to conventional antibiotics with different structures. Curr. Microbiol. 59, 147-153
11. Darveau, R. P., Cunningham, M. D., Seachord, C. L., Cassiano- Clough, L., Cosand, W. L., Blake, J., and Watkins, C. S. (1991) Beta-lactam antibiotics potentiate magainin 2 antimicrobial activity in vitro and in vivo. Antimicrob. Agents Chemother. 35, 1153-1159
12. Minahk, C. J., Dupuy, F., and Morero, R. D. (2004) Enhancement of antibiotic activity by sub-lethal concentrations of enterocin CRL35. J. Antimicrob. Chemother. 53, 240-246
13. Vaara, M., Fox, J., Loidl, G., Siikanen, O., Apajalahti, J., Hansen, F., Frimodt-Moller, N., Nagai, J., Takano, M., and Vaara, T. (2008) Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob. Agents Chemother. 52, 3229-3236
14. Ulvatne, H., Karoliussen, S., Stiberg, T., Rekdal, O., and Svendsen, J. S. (2001) Short antibacterial peptides and erythromycin act synergically against Escherichia coli. J. Antimicrob. Chemother. 48, 203-208
15. Giacometti, A., Cirioni, O., Barchiesi, F., and Scalise, G. (2000) In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics. Diagn. Microbiol. Infect. Dis. 38, 115-118
16. Cirioni, O., Silvestri, C., Ghiselli, R., Orlando, F., Riva, A., Mocchegiani, F., Chiodi, L., Castelletti, S., Gabrielli, E., Saba, V., Scalise, G., and Giacometti, A. (2008) Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. J. Antimicrob. Chemother. 62, 1332-1338
17. Cirioni, O., Ghiselli, R., Orlando, F., Silvestri, C., Mocchegiani, F., Rocchi, M., Chiodi, L., Abbruzzetti, A., Saba, V., Scalise, G., and Giacometti, A. (2007) Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. Crit. Care. Med. 35, 1717-1723
18. Anantharaman, A., Rizvi, M. S., and Sahal, D. (2010) Synergy with rifampin and kanamycin enhances potency, kill kinetics, and selectivity of de novo-designed antimicrobial peptides. Antimicrob. Agents Chemother. 54, 1693-1699
19. Parisien, A., Allain, B., Zhang, J., Mandeville, R., and Lan, C. Q. (2008) Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J. Appl. Microbiol. 104, 1-13
20. Jenssen, H., Hamill, P., and Hancock, R. E. (2006) Peptide antimicrobial agents. Clin. Microbiol. Rev. 19, 491-511
21. Yeaman, M. R., and Yount, N. Y. (2003) Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55, 27-55
22. Bradshaw, J. (2003) Cationic antimicrobial peptides: issues for potential clinical use. BioDrugs 17, 233-240
23. Gordon, Y. J., Romanowski, E. G., and McDermott, A. M. (2005) A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye. Res. 30, 505-515
24. Marr, A. K., Gooderham, W. J., and Hancock, R. E. (2006) Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 6, 468-472
25. Gunn, J. S. (2008) The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. Trends Microbiol. 16, 284-290
26. Otto, M. (2009) Bacterial sensing of antimicrobial peptides. Contrib. Microbiol. 16, 136-149
27. Rotem, S., and Mor, A. (2009) Antimicrobial peptide mimics for improved therapeutic properties. Biochim. Biophys. Acta. 1788, 1582-1592
28. Epand, R. M., Epand, R. F., and Savage, P. B. (2008) Ceragenins (cationic steroid compounds), a novel class of antimicrobial agents. Drug News Perspect. 21, 307-311
29. Scott, R. W., DeGrado, W. F., and Tew, G. N. (2008) De novo designed synthetic mimics of antimicrobial peptides. Curr. Opin. Biotechnol. 19, 620-627
30. Radzishevsky, I. S., Rotem, S., Bourdetsky, D., Navon-Venezia, S., Carmeli, Y., and Mor, A. (2007) Improved antimicrobial peptides based on acyl-lysine oligomers. Nat. Biotechnol. 25, 657-659
31. Radzishevsky, I., Krugliak, M., Ginsburg, H., and Mor, A. (2007) Antiplasmodial activity of lauryl-lysine oligomers. Antimicrob. Agents. Chemother. 51, 1753-1759
32. Radzishevsky, I. S., Kovachi, T., Porat, Y., Ziserman, L., Zaknoon, F., Danino, D., and Mor, A. (2008) Structure-activity relationships of antibacterial acyl-lysine oligomers. Chem. Biol. 15, 354-362
33. Rotem, S., Radzishevsky, I. S., Bourdetsky, D., Navon-Venezia, S., Carmeli, Y., and Mor, A. (2008) Analogous oligo-acyl-lysines with distinct antibacterial mechanisms. FASEB J. 22, 2652-2661
34. Epand, R. M., Rotem, S., Mor, A., Berno, B., and Epand, R. F. (2008) Bacterial membranes as predictors of antimicrobial potency. J. Am. Chem. Soc. 130, 14346-14352
35. Livne, L., Kovachi, T., Sarig, H., Epand, R. F., Zaknoon, F., Epand, R. M., and Mor, A. (2009) Design and characterization of a broad-spectrum bactericidal acyl-lysyl oligomer. Chem. Biol. 16, 1250-1258
36. Sarig, H., Livne, L., Held-Kuznetsov, V., Zaknoon, F., Ivankin, A., Gidalevitz, D., and Mor, A. (2010) A miniature mimic of host defense peptides with systemic antibacterial efficacy. FASEB J. 24, 1904-1913
37. Held-Kuznetsov, V., Rotem, S., Assaraf, Y. G., and Mor, A. (2009) Host-defense peptide mimicry for novel antitumor agents. FASEB J. 23, 4299-4307
38. Fields, G. B., and Noble, R. L. (1990) Solid-phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35, 161-214
39. Hoben, H. J., and Somasegaran, P. (1982) Comparison of the pour, spread, and drop plate methods for enumeration of rhizobium spp. in inoculants made from presterilized peat. Appl. Environ. Microbiol. 44, 1246-1247
40. Rydlo, T., Rotem, S., and Mor, A. (2006) Antibacterial properties of dermaseptin S4 derivatives under extreme incubation conditions. Antimicrob. Agents Chemother. 50, 490-497 (Pubitemid 43190957)
41. Bohnert, J. A., and Kern, W. V. (2005) Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob. Agents Chemother. 49, 849-852
42. Lorenzen, A., and Kennedy, S. W. (1993) A fluorescence-based protein assay for use with a microplate reader. Anal. Biochem. 214, 346-348
43. Navon-Venezia, S., Feder, R., Gaidukov, L., Carmeli, Y., and Mor, A. (2002) Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob. Agents Chemother. 46, 689-694
44. Hardman, J. G., Limbird, L. E., Molinoff, P. B., and Ruddon, R. W. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, Columbus, OH, USA
45. Papahadjopoulos, D., Vail, W. J., Jacobson, K., and Poste, G. (1975) Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim. Biophys. Acta. 394, 483-491
46. Zarif, L. (2002) Elongated supramolecular assemblies in drug delivery. J. Control. Release 81, 7-23
47. Zarif, L. (2005) Drug delivery by lipid cochleates. Methods Enzymol. 391, 314-329
48. Ramani, K., and Balasubramanian, S. V. (2003) Fluorescence properties of Laurdan in cochleate phases. Biochim. Biophys. Acta. 1618, 67-78
49. Miclea, R. D., Varma, P. R., Peng, A., and Balu-Iyer, S. V. (2007) Development and characterization of lipidic cochleate containing recombinant factor VIII. Biochim. Biophys. Acta. 1768, 2890-2898
50. Parasassi, T., De Stasio, G., Ravagnan, G., Rusch, R. M., and Gratton, E. (1991) Quantitation of lipid phases in phospholipid vesicles by the generalized polarization of Laurdan fluorescence. Biophys. J. 60, 179-189
51. Parasassi, T., Di Stefano, M., Loiero, M., Ravagnan, G., and Gratton, E. (1994) Cholesterol modifies water concentration and dynamics in phospholipid bilayers: a fluorescence study using Laurdan probe. Biophys. J. 66, 763-768
52. Moghimi, S. M., and Szebeni, J. (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid. Res. 42, 463-478
53. Auerbach, T., Mermershtain, I., Davidovich, C., Bashan, A., Belousoff, M., Wekselman, I., Zimmerman, E., Xiong, L., Klepacki, D., Arakawa, K., Kinashi, H., Mankin, A. S., and Yonath, A. (2010) The structure of ribosome-lankacidin complex reveals ribosomal sites for synergistic antibiotics. Proc. Natl. Acad. Sci. U. S. A. 107, 1983-1988
54. Yonath, A. (2005) Antibiotics targeting ribosomes: resistance, selectivity, synergism and cellular regulation. Annu. Rev. Biochem. 74, 649-679
55. Acar, J. F. (2000) Antibiotic synergy and antagonism. Med. Clin. North. Am. 84, 1391-1406
56. Mor, A., Hani, K., and Nicolas, P. (1994) The vertebrate peptide antibiotics dermaseptins have overlapping structural features but target specific microorganisms. J. Biol. Chem. 269, 31635-31641
57. Levy, O., Ooi, C. E., Weiss, J., Lehrer, R. I., and Elsbach, P. (1994) Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli. J. Clin. Invest. 94, 672-682
58. Steenbergen, J. N., Mohr, J. F., and Thorne, G. M. (2009) Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J. Antimicrob. Chemother. 64, 1130-1138
59. Jana, S., and Deb, J. K. (2006) Molecular understanding of aminoglycoside action and resistance. Appl. Microbiol. Biotechnol. 70, 140-150
60. Wright, G. D. (2003) Mechanisms of resistance to antibiotics. Curr. Opin. Chem. Biol. 7, 563-569
61. Rhodius, V. A., Suh, W. C., Nonaka, G., West, J., and Gross, C. A. (2006) Conserved and variable functions of the sigmaE stress response in related genomes. PLoS Biol. 4, e2
62. Boor, K. J. (2006) Bacterial stress responses: what doesn't kill them can make then stronger. PLoS Biol. 4, e23
63. Bracho, G., Lastre, M., del Campo, J., Zayas, C., Gonzalez, D., Gil, D., Acevedo, R., Taboada, C., Solis, R. L., and Perez, O. (2006) Proteoliposome derived cochleate as novel adjuvant. Vaccine. 24(Suppl. 2), S2-30-S2-31
64. Perez, O., Bracho, G., Lastre, M., Mora, N., del Campo, J., Gil, D., Zayas, C., Acevedo, R., Gonzalez, D., Lopez, J. A., Taboada, C., Turtle, C., and Solis, R. L. (2004) Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol. Cell Biol. 82, 603-610
65. Campo, J. D., Zayas, C., Romeu, B., Acevedo, R., Gonzalez, E., Bracho, G., Cuello, M., Cabrera, O., Balboa, J., and Lastre, M. (2009) Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses. Methods 49, 301-308
66. Del Campo, J., Lastre, M., Bracho, G., Rodriguez, T., Gil, D., Zayas, C., Taboada, C., Acevedo, R., Perez, D. R., and Perez, O. (2006) Immunological evaluation of bacterial derived Cochleate and proteoliposome as mucosal adjuvants. Vaccine 24(Suppl. 2), S2-50 -S2-51
67. Mannino, R. J., Canki, M., Feketeova, E., Scolpino, A. J., Wang, Z., Zhang, F., Kheiri, M. T., and Gould-Fogerite, S. (1998) Targeting immune response induction with cochleate and liposome- based vaccines. Adv. Drug. Deliv. Rev. 32, 273-287
68. Perez, O., Bracho, G., Lastre, M., Zayas, C., Gonzalez, D., Gil, D., del Campo, J., Acevedo, R., Taboada, C., Rodriguez, T., Fajardo, M. E., Sierra, G., Campa, C., Mora, N., Barbera, R., and Solis, R. L. (2006) Proteliposome-derived cochleate as an immunomodulator for nasal vaccine. Vaccine 24(Suppl. 2), S2-52-S2-53
69. Syed, U. M., Woo, A. F., Plakogiannis, F., Jin, T., and Zhu, H. (2008) Cochleates bridged by drug molecules. Int. J. Pharm. 363, 118-125
70. Walker, S. A., Kennedy, M. T., and Zasadzinski, J. A. (1997) Encapsulation of bilayer vesicles by self-assembly. Nature 387, 61-64
71. Delmas, G., Park, S., Chen, Z. W., Tan, F., Kashiwazaki, R., Zarif, L., and Perlin, D. S. (2002) Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob. Agents Chemother. 46, 2704-2707
72. Santangelo, R., Paderu, P., Delmas, G., Chen, Z. W., Mannino, R., Zarif, L., and Perlin, D. S. (2000) Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob. Agents. Chemother. 44, 2356-2360
73. Sternberg, B. (1996) Liposomes as a Model for Membrane Structures and Structural Transformations: A Liposome Album, Vol. 4, CRC Press, Boca Raton, FL, USA
74. Lewis, J. S., 2nd, Herrera, M., Wickes, B., Patterson, J. E., and Jorgensen, J. H. (2007) First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob. Agents Chemother. 51, 4015-4021
75. Manges, A. R., Johnson, J. R., Foxman, B., O'Bryan, T. T., Fullerton, K. E., and Riley, L. W. (2001) Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N. Engl. J. Med. 345, 1007-1013
76. Zaknoon, F., Sarig, H., Rotem, S., Livne, L., Ivankin, A., Gidalevitz, D., and Mor, A. (2009) Antibacterial properties and mode of action of a short acyl-lysyl oligomer. Antimicrob. Agents Chemother. 53, 3422-3429
77. Epand, R. F., Sarig, H., Mor, A., and Epand, R. M. (2009) Cell-wall interactions and the selective bacteriostatic activity of a miniature oligo-acyl-lysyl. Biophys. J. 97, 2250-2257